Advertisement

Device Therapy for Sudden Cardiac Death Prophylaxis After Acute Coronary Syndrome: When and Why?

  • Faheemullah Beg
  • Miguel Valderrabano
  • Paul SchurmannEmail author
Management of Acute Coronary Syndromes (H Jneid, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Management of Acute Coronary Syndromes

Abstract

Implantable cardioverter-defibrillators (ICDs) are a powerful tool in preventing sudden cardiac death due to ventricular arrhythmias in ischemic cardiomyopathy. ICD indications and timing in acute coronary syndromes are unclear.

Purpose of Review

We reviewed several trials that delineated the indications for a cardiac defibrillator in patients with coronary artery disease.

Recent Findings

The role of cardiac defibrillators in secondary prevention has been well established by AVID, CIDS, and CASH trials. AVID showed reduction in both all-cause mortality and arrhythmic death while the two smaller trials showed only improvement in arrhythmic death. Similarly, trials like MADIT, CABG Patch, MUSTT, MADIT-II, DINAMIT, and the IRIS trial have fine-tuned the indications for ICD in primary prevention of sudden cardiac death. Benefits of an ICD were most pronounced in those with reduced ejection fraction and 40 days or more since myocardial infarction or in those who were not immediately post revascularization. The recent VEST trial aimed to study wearable cardioverter-defibrillators (WCDs) in patients who did not have an indication for an implantable defibrillator. The arrhythmic deaths (1.6% vs. 2.4%) were not reduced by the WCD.

Summary

Based on consistent reduction in arrhythmic death in all primary and secondary prevention trials, defibrillators are effective in carefully selected patients.

Keywords

Sudden cardiac death Implantable cardioverter-defibrillator Wearable cardioverter-defibrillator Ventricular arrhythmias Acute coronary syndrome 

Notes

Compliance with Ethical Standards

Conflict of Interest

Faheemullah Beg, Miguel Valderrabano, and Paul Schurmann declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as:•• Of major importance

  1. 1.
    Zipes DP, Wellens HJ. Sudden cardiac death. Circulation. 1998;98(21):2334–51.CrossRefGoogle Scholar
  2. 2.
    ACC/AHA/HRS. 2006 key data elements and definitions for electrophysiological studies and procedures. Circulation. 2006;114(23):2534–70.CrossRefGoogle Scholar
  3. 3.
    Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67–e492.CrossRefGoogle Scholar
  4. 4.
    Chelly J, Mongardon N, Dumas F, Varenne O, Spaulding C, Vignaux O, et al. Benefit of an early and systematic imaging procedure after cardiac arrest: insights from the PROCAT (Parisian Region Out of Hospital Cardiac Arrest) registry. Resuscitation. 2012;83(12):1444–50.CrossRefGoogle Scholar
  5. 5.
    Bhar-Amato J, Davies W, Agarwal S. Ventricular arrhythmia after acute myocardial infarction: ‘The Perfect Storm’. Arrhythmia Electrophysiol Rev. 2017;6(3):134–9.CrossRefGoogle Scholar
  6. 6.
    Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324(12):781–8.CrossRefGoogle Scholar
  7. 7.
    Kuck KH, Schaumann A, Eckardt L, Willems S, Ventura R, Delacretaz E, et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet. 2010;375(9708):31–40.CrossRefGoogle Scholar
  8. 8.
    Sapp JL, Wells GA, Parkash R, Stevenson WG, Blier L, Sarrazin JF, et al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med. 2016;375(2):111–21.CrossRefGoogle Scholar
  9. 9.
    Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Circulation. 2018;138(13):e272–391.PubMedGoogle Scholar
  10. 10.
    Antiarrhythmics versus Implantable Defibrillators I. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337(22):1576–83.CrossRefGoogle Scholar
  11. 11.
    •• Causes of death in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. J Am Coll Cardiol. 1999;34(5):1552–9. Landmark article showing evidence to use implantable defibrillators for sudden cardiac death. Google Scholar
  12. 12.
    •• Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, et al. Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101(11):1297–302. Landmark article showing evidence to use implantable defibrillators for sudden cardiac death. CrossRefGoogle Scholar
  13. 13.
    Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102(7):748–54.CrossRefGoogle Scholar
  14. 14.
    Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study. Eur Heart J. 2000;21(24):2071–8.CrossRefGoogle Scholar
  15. 15.
    Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335(26):1933–40.CrossRefGoogle Scholar
  16. 16.
    Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877–83.CrossRefGoogle Scholar
  17. 17.
    Greenberg H, Case RB, Moss AJ, Brown MW, Carroll ER, Andrews ML, et al. Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II). J Am Coll Cardiol. 2004;43(8):1459–65.CrossRefGoogle Scholar
  18. 18.
    Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341(25):1882–90.CrossRefGoogle Scholar
  19. 19.
    Schrage B, Uijl A, Benson L, Westermann D, Stahlberg M, Stolfo D, et al. Association between use of primary prevention implantable cardioverter-defibrillators and mortality in patients with heart failure: a prospective propensity-score matched analysis from the Swedish Heart Failure Registry. Circulation. 2019.Google Scholar
  20. 20.
    Bauer A, Klemm M, Rizas KD, Hamm W, von Stulpnagel L, Dommasch M, et al. Prediction of mortality benefit based on periodic repolarisation dynamics in patients undergoing prophylactic implantation of a defibrillator: a prospective, controlled, multicentre cohort study. Lancet. 2019.Google Scholar
  21. 21.
    Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351(24):2481–8.CrossRefGoogle Scholar
  22. 22.
    Steinbeck G, Andresen D, Seidl K, Brachmann J, Hoffmann E, Wojciechowski D, et al. Defibrillator implantation early after myocardial infarction. N Engl J Med. 2009;361(15):1427–36.CrossRefGoogle Scholar
  23. 23.
    Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med. 1997;337(22):1569–75.CrossRefGoogle Scholar
  24. 24.
    Bigger JT Jr, Whang W, Rottman JN, Kleiger RE, Gottlieb CD, Namerow PB, et al. Mechanisms of death in the CABG Patch trial: a randomized trial of implantable cardiac defibrillator prophylaxis in patients at high risk of death after coronary artery bypass graft surgery. Circulation. 1999;99(11):1416–21.CrossRefGoogle Scholar
  25. 25.
    Haanschoten, D. (2019). Long-term outcome of the Defibrillator After Primary Angioplasty (DAPA) trial. European Society of Cardiology Congress, Paris, France.Google Scholar
  26. 26.
    •• Olgin JE, Pletcher MJ, Vittinghoff E, Wranicz J, Malik R, Morin DP, et al. Wearable cardioverter-defibrillator after myocardial infarction. N Engl J Med. 2018;379(13):1205–15. This article shows new evidence on wearable cardiac-defibrillator for prevention of sudden cardiac death, which may impact the current guideline and its use. CrossRefGoogle Scholar
  27. 27.
    Kutyifa V, Moss AJ, Klein H, Biton Y, McNitt S, MacKecknie B, et al. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry). Circulation. 2015;132(17):1613–9.CrossRefGoogle Scholar
  28. 28.
    Patel KH, Lambiase PD. The subcutaneous ICD-current evidence and challenges. Cardiovasc Diagn Ther. 2014;4(6):449–59.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Chieng D, Paul V, Denman R. Current device therapies for sudden cardiac death prevention - the ICD, subcutaneous ICD and wearable ICD. Heart Lung Circ. 2019;28(1):65–75.CrossRefGoogle Scholar
  30. 30.
    Burke MC, Gold MR, Knight BP, Barr CS, Theuns D, Boersma LVA, et al. Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-year results from a pooled analysis of the IDE Study and EFFORTLESS Registry. J Am Coll Cardiol. 2015;65(16):1605–15.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  • Faheemullah Beg
    • 1
  • Miguel Valderrabano
    • 2
  • Paul Schurmann
    • 2
    Email author
  1. 1.Department of CardiologyHouston Methodist Debakey Heart & Vascular CenterHoustonUSA
  2. 2.Division of Cardiac Electrophysiology, Department of CardiologyHouston Methodist Debakey Heart & Vascular CenterHoustonUSA

Personalised recommendations